|
FDA Delaying Decision on Gilead’s Truvada sNDA for HIV Prevention
The FDA has informed Gilead Sciences it needs at least three more months to weigh its Truvada sNDA for HIV prevention, AIDS advocates say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives